24 completed, 11 terminated, 6 active not recruiting, 4 withdrawn. 51 Phase 1, 17 Phase 2.
Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma | Phase 1 / Phase 2 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 27 | 2025-04-01 | 2026-07-10 |
| A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C) - Advanced Solid Tumor, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Immuneering Corporation | 209 | 2022-10-31 | 2026-10-20 |
| E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma Dabrafenib, MEK-1/MEKK-1 Inhibitor E6201, Biospecimen Collection - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Terminated | Mayo Clinic | 13 | 2022-10-20 | 2025-08-19 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 16 | 2021-08-19 | 2026-11-18 |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib - BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present | Phase 1 | Suspended | City of Hope Medical Center | 6 | 2020-09-14 | 2026-10-15 |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Dabrafenib, LTT462, Trametinib - BRAF V600 Colorectal Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2020-07-22 | 2025-12-24 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Dabrafenib, Trametinib, Hydroxychloroquine - Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration | Phase 1 / Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 57 | 2020-01-17 | 2026-09-11 |
| INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Trametinib, Dabrafenib, INCB039110 - Melanoma | Phase 1 | Terminated | Massachusetts General Hospital | 1 | 2019-05-29 | 2023-09-22 |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma MCS110, Dabrafenib, Trametinib - Melanoma | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 6 | 2018-09-10 | 2024-07-31 |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) E6201, E6201 plus dabrafenib - Malignant Melanoma, Brain Metastases | Phase 1 | Terminated | Spirita Oncology, LLC | 4 | 2018-07-02 | 2022-05-20 |
| Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma Dabrafenib, Trametinib, Hydroxychloroquine - Melanoma | Phase 1 / Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 63 | 2018-01-23 | 2021-04-28 |
| A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma APR-246, Dabrafenib - Melanoma | Phase 1 / Phase 2 | Terminated | Aprea Therapeutics | 3 | 2018-01-18 | 2019-07-31 |
| Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib - Melanoma, BRAF Gene Mutation | Phase 1 | Unknown | West Cancer Center | 4 | 2017-06-25 | 2020-10-12 |
| A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Dabrafenib, Trametinib - Multiple Myeloma | Phase 1 | Active not recruiting | Massachusetts General Hospital | 30 | 2017-06-21 | 2026-07-31 |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma Dabrafenib, Trametinib - Melanoma | Phase 1 | Withdrawn | GlaxoSmithKline | 2017-05-01 | 2018-09-14 | |
| BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab - Melanoma | Phase 1 / Phase 2 | Completed | Haukeland University Hospital | 74 | 2017-02-13 | 2025-01-14 |
| Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma Dabrafenib, Trametinib, Phenformin - Melanoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 18 | 2017-01-01 | 2025-01-23 |
Showing 20 of 51. Sign in to see all of them.
Melanoma (27) · Neoplasms (13) · Neoplasm Metastasis (7) · Brain Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Glioma (2) · Hematologic Neoplasms (2) · Multiple Myeloma (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Renal Insufficiency (2) · Thyroid Carcinoma, Anaplastic (2) · Adenocarcinoma (1) · Anemia (1) · Blast Crisis (1)
GlaxoSmithKline (10) · National Cancer Institute (NCI) (7) · Novartis Pharmaceuticals (7) · Massachusetts General Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Aprea Therapeutics (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Haukeland University Hospital (1) · Immuneering Corporation (1) · JS InnoPharm, LLC (1) · Kartos Therapeutics, Inc. (1) · Manisha Shah (1) · Mayo Clinic (1)
United States (43) · Australia (10) · United Kingdom (8) · Canada (6) · France (5) · Spain (5) · Belgium (4) · Italy (4) · Germany (3) · Israel (2) · Japan (2) · Netherlands (2) · Denmark (1) · Norway (1) · Poland (1)
Ryan J Sullivan (2) · Ahmad Awada, PhD (1) · Antoni Ribas (1) · Arthur Frankel, MD (1) · Ashley Plant-Fox, MD (1) · Bart Neyns, MD PhD (1) · David M. Miller, MD, PhD (1) · Elizabeth I Buchbinder, MD (1) · Eric J Sherman (1) · Hani M Babiker, MD (1) · Hani M. Babiker, MD (1) · Hussein Tawbi, MD (1) · Jason A Chesney, MD, PhD (1)
PMID 36884302, PMID 23645591, PMID 24408395, PMID 24577748, PMID 28879519, PMID 29243287, PMID 29880583, PMID 30181415, PMID 31171878, PMID 31171879, PMID 31506385, PMID 31811016, PMID 33288749, PMID 33762304, PMID 33932130, PMID 34331515, PMID 34801354, PMID 35156519, PMID 36375115, PMID 37042037, PMID 38261444, PMID 39863139, PMID 40721981
U01CA062490 (4), UM1CA186709 (4), P30CA006516 (2), UM1CA186716 (2), 2015 (1), P30CA008748 (1), P30CA015083 (1), R01CA246553 (1), R01CA258751 (1), U01CA069856 (1), U01CA069912 (1), U01CA132123 (1), U01CA132194 (1), U10CA032102 (1), U10CA180830 (1)